Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

English version České info

Background:
A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission.

Methods and Findings:
6,537 infants aged 6–12 wk and 8,923 children aged 5–17 mo were randomized to receive three doses of RTS,S/AS01 or comparator vaccine.

VE against clinical malaria in children during the 18 mo after vaccine dose 3 (per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p<0.01 across all sites). VE during the 20 mo after vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%), respectively (ITT).

VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%], ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization.

Post-vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and from 117 to 335 EU/ml in infants (per protocol).

VE waned over time in both age categories (Schoenfeld residuals p<0.001). The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365 and from −1 to 49, respectively; corresponding ranges among infants were −10 to 1,402 and −13 to 37, respectively (ITT). Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively.

Conclusions:
RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current malaria control in Africa.

Trial registration:
www.ClinicalTrials.gov NCT00866619

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLoS Med 11(7): e32767. doi:10.1371/journal.pmed.1001685
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001685

Souhrn

Trial registration:
www.ClinicalTrials.gov NCT00866619

Please see later in the article for the Editors' Summary

Zdroje

1. MurrayCJ, RosenfeldLC, LimSS, AndrewsKG, ForemanKJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413–431.

2. EiseleTP, LarsenDA, WalkerN, CibulskisRE, YukichJO, et al. (2012) Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001–2010. Malar J 11: 93.

3. World Health Organization (2012) World malaria report 2012. Geneva: World Health Organization.

4. ProtopopoffN, MatowoJ, MalimaR, KavisheR, KaayaR, et al. (2013) High level of resistance in the mosquito Anopheles gambiae to pyrethroid insecticides and reduced susceptibility to bendiocarb in north-western Tanzania. Malar J 12: 149.

5. DondorpAM, NostenF, YiP, DasD, PhyoAP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.

6. NoorAM, KinyokiDK, MundiaCW, KabariaCW, MutuaJW, et al. (2014) The changing risk of Plasmodium falciparum malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity. Lancet 383: 1739–1747.

7. StouteJA, SlaouiM, HeppnerDG, MominP, KesterKE, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336: 86–91.

8. BojangKA, MilliganPJ, PinderM, VigneronL, AllouecheA, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927–1934.

9. AponteJJ, AideP, RenomM, MandomandoI, BassatQ, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543–1551.

10. AbdullaS, OberholzerR, JumaO, KubhojaS, MacheraF, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359: 2533–2544.

11. KesterKE, CummingsJF, Ofori-AnyinamO, OckenhouseCF, KrzychU, et al. (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337–346.

12. BejonP, LusinguJ, OlotuA, LeachA, LievensM, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521–2532.

13. LellB, AgnandjiS, von GlasenappI, HaertleS, OyakhiromenS, et al. (2009) A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 4: e7611.

14. AsanteKP, AbdullaS, AgnandjiS, LyimoJ, VekemansJ, et al. (2011) Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 11: 741–749.

15. RTS,S Clinical Trials Partnership (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284–2295.

16. RTS,S Clinical Trials Partnership (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863–1875.

17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996) ICH harmonised tripartite guideline. Good clinical practice: consolidated guideline. Geneva: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.

18. LeachA, VekemansJ, LievensM, Ofori-AnyinamO, CahillC, et al. (2011) Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 10: 224.

19. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2011) MedDRA® term selection: points to consider. ICH-endorsed guide for MedDRA users. Geneva: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 49 p.

20. ClementF, DewarV, Van BraeckelE, DesombereI, DewerchinM, et al. (2012) Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J 11: 384.

21. OlotuA, FeganG, WambuaJ, NyangwesoG, AwuondoKO, et al. (2013) Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 368: 1111–1120.

22. BejonP, WhiteMT, OlotuA, BojangK, LusinguJP, et al. (2013) Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 13: 319–327.

23. GattonML, ChengQ (2004) Modeling the development of acquired clinical immunity to Plasmodium falciparum malaria. Infect Immun 72: 6538–6545.

24. GbedandeK, VaraniS, IbitokouS, HoungbegnonP, BorgellaS, et al. (2013) Malaria modifies neonatal and early-life Toll-like receptor cytokine responses. Infect Immun 81: 2686–2696.

25. DaubyN, GoetghebuerT, KollmannTR, LevyJ, MarchantA (2012) Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis 12: 330–340.

26. Owusu-AgyeiS, AnsongD, AsanteK, Kwarteng OwusuS, OwusuR, et al. (2009) Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4: e7302.

27. SwysenC, VekemansJ, BrulsM, OyakhiromeS, DrakeleyC, et al. (2011) Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 10: 223.

28. VekemansJ, MarshK, GreenwoodB, LeachA, KaboreW, et al. (2011) Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malar J 10: 221.

29. LengelerC (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004: CD000363.

30. GreenwoodBM, GreenwoodAM, BradleyAK, SnowRW, ByassP, et al. (1988) Comparison of two strategies for control of malaria within a primary health care programme in the Gambia. Lancet 1: 1121–1127.

31. ter KuileFO, TerlouwDJ, Phillips-HowardPA, HawleyWA, FriedmanJF, et al. (2003) Impact of permethrin-treated bed nets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: cross-sectional survey. Am J Trop Med Hyg 68: 100–107.

32. WilliamsonWA, GreenwoodBM (1978) Impairment of the immune response to vaccination after acute malaria. Lancet 1: 1328–1329.

33. MarkusMB, FinchamJE (2007) Helminthiasis, bystander diseases and vaccines: analysis of interaction. Trends Parasitol 23: 517–519.

34. HaySI, GuerraCA, GethingPW, PatilAP, TatemAJ, et al. (2009) A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6: e1000048.